Close

Roth Capital Cuts PT on Cerulean Pharma (CERU) to $2.50 Following CRLX101 Combo Phase 2 Data

Go back to Roth Capital Cuts PT on Cerulean Pharma (CERU) to $2.50 Following CRLX101 Combo Phase 2 Data